RxDoctor Payments Data

Catharine Stephenson

Family · Panama City, FLNPI 1043495278

Payments from drug & device makers

$2,040in general payments, 2019–2025

Across 84 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$422
  • AstraZeneca$324
  • Amgen$224
  • Aurinia Pharma U.S., Inc.$171
  • Fresenius USA Marketing, Inc.$164
  • Akebia Therapeutics Inc$155
  • plus $580 from 8 others

What the payments were for

  • Food & beverage$2,00198%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,040 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$12,268
Medicare patients
36
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide15$39,255
AuryxiaFerric Citrate27$29,399
EliquisApixaban13$20,014
Sevelamer Carbonate38$16,315
TradjentaLinagliptin15$10,844
ClinolipidFat Emulsion/Olive/Soy/Phospho31$9,923
TrulancePlecanatide11$6,518
ProsolParenteral Amino Acid 20% No.115$3,187
Calcium Acetate33$2,714
Ondansetron OdtOndansetron26$1,719
Midodrine Hcl23$1,635
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,361
Ondansetron Hcl61$1,207
Albuterol Sulfate HfaAlbuterol Sulfate41$1,039
Carvedilol105$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$164$39,25515 claims
Akebia Therapeutics IncAuryxia$155$29,39927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →